Trial Profile
A Phase III, Randomized, Open-label Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-061
- Sponsors Merck Sharp & Dohme Corp.
- 06 Jun 2023 Results assessing Integrated survival analysis presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 13 Apr 2022 Results (n=274) assessing the association between tumor gene expression signatures and clinical outcomes, presented at the 113th Annual Meeting of the American Association for Cancer Research.
- 21 Sep 2021 Results assessing genomic landscape of late-stage gastric cancer from these two studies (KEYNOTE-059 and KEYNOTE-061) presented at the 46th European Society for Medical Oncology Congress